Patents by Inventor Ulla Hedner

Ulla Hedner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
    Publication number: 20190307862
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 10, 2019
    Inventor: Ulla Hedner
  • Single dose administration of factor VIIa
    Patent number: 10350276
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 16, 2019
    Assignee: Novo Nordisk HealthCare AG
    Inventor: Ulla Hedner
  • SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
    Publication number: 20190091303
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: December 10, 2018
    Publication date: March 28, 2019
    Inventor: Ulla Hedner
  • SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
    Publication number: 20190000934
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: February 23, 2018
    Publication date: January 3, 2019
    Inventor: Ulla Hedner
  • SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
    Publication number: 20170296634
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 19, 2017
    Inventor: Ulla Hedner
  • SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
    Publication number: 20170106060
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: August 29, 2016
    Publication date: April 20, 2017
    Inventor: Ulla Hedner
  • SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
    Publication number: 20160101162
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Inventor: Ulla Hedner
  • SINGLE-DOSE ADMINISTRATION OF FACTOR VIIa
    Publication number: 20150209417
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: April 10, 2015
    Publication date: July 30, 2015
    Inventor: Ulla Hedner
  • Single-dose administration of Factor VIIa
    Patent number: 9029324
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Grant
    Filed: May 28, 2008
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk Healthcare AG
    Inventor: Ulla Hedner
  • Single-Dose Administration of Factor VIIa
    Publication number: 20080261886
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.
    Type: Application
    Filed: May 28, 2008
    Publication date: October 23, 2008
    Applicant: Novo Nordisk HealthCare A/G
    Inventor: Ulla Hedner
  • Single-dose administration of factor VIIa
    Patent number: 7419949
    Abstract: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of Factor VIIa or a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ?g/kg Factor VIIa or Factor VIIa equivalent.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: September 2, 2008
    Assignee: Novo Noridsk HealthCare A/G
    Inventor: Ulla Hedner
  • Combined Use of Factor VII Polypeptides and Factor VIII Polypeptides
    Publication number: 20080076702
    Abstract: The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide for manufacture of a medicament for pharmaceutical use as well as methods for prevention or treatment of bleeding episodes in subjects.
    Type: Application
    Filed: October 4, 2007
    Publication date: March 27, 2008
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Jens Knudsen, Ulla Hedner, Rasmus Rojkjaer
  • Combined Use of Factor VII Polypeptides and Factor IX Polypeptides
    Publication number: 20080075711
    Abstract: The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor IX or factor IX-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor IX or factor IX-related polypeptide for manufacture of a medicament for pharmaceutical use as well as methods for prevention or treatment of bleeding episodes in subjects.
    Type: Application
    Filed: October 4, 2007
    Publication date: March 27, 2008
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Jens Knudsen, Ulla Hedner, Rasmus Rojkjaer
  • PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII
    Publication number: 20070280920
    Abstract: The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or prophylaxis of bleeding episodes.
    Type: Application
    Filed: May 30, 2007
    Publication date: December 6, 2007
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Lars Petersen, Ulla Hedner, Rasmus Rojkjaer
  • Combined use of factor VII polypeptides and factor VIII polypeptides
    Publication number: 20060276398
    Abstract: The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide for manufacture of a medicament for pharmaceutical use as well as methods for prevention or treatment of bleeding episodes in subjects.
    Type: Application
    Filed: July 25, 2006
    Publication date: December 7, 2006
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Jens Knudsen, Ulla Hedner, Rasmus Rojkjaer
  • Combined use of factor VII polypeptides and factor IX polypeptides
    Publication number: 20060211621
    Abstract: The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor IX or factor IX-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor IX or factor IX-related polypeptide for manufacture of a medicament for pharmaceutical use as well as methods for prevention or treatment of bleeding episodes in subjects.
    Type: Application
    Filed: May 18, 2006
    Publication date: September 21, 2006
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Jens Knudsen, Ulla Hedner, Rasmus Rojkjaer
  • Pharmaceutical composition comprising a factor VIIa and a factor XIII
    Publication number: 20060199766
    Abstract: The present invention relates to the use of a factor VIIa and a factor XIII in the treatment or pro-phylaxis of bleeding episodes.
    Type: Application
    Filed: March 28, 2006
    Publication date: September 7, 2006
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Lars Petersen, Ulla Hedner, Rasmus Rojkjaer
  • Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
    Publication number: 20060025336
    Abstract: Compositions comprising factor VII or a factor VII-related polypeptide and aprotinin or an aprotinin-related polypeptide and uses thereof are provided.
    Type: Application
    Filed: February 10, 2005
    Publication date: February 2, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Rasmus Rojkjaer, Ulla Hedner
  • Modified factor VII
    Publication number: 20040197370
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The modified Factor VII may be used in conjunction with stents to inhibit coagulation, vascular restenosis, and/or platelet deposition.
    Type: Application
    Filed: December 17, 2003
    Publication date: October 7, 2004
    Applicant: Novo Nordisk Health Care AG
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified factor VII
    Publication number: 20040087498
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Application
    Filed: October 1, 2002
    Publication date: May 6, 2004
    Applicant: Novo Nordisk Health Care AG
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard